Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Struggling to keep your New Year's resolutions? Here's how to keep yourself on track - 2In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
- 3The Fate of Mechanical technology: 5 Headways Forming Tomorrow
- 4Israel kidnaps PIJ terrorist in covert op. in Hamas-controlled Gaza in pursuit of Ran Gvili
- 5A Sweet Choice: Pick Your #1 Cake!
- From School Dropout to Example of overcoming adversity: My Excursion
- 'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- 'The Secret Lives of Mormon Wives' Season 3 premieres tomorrow. Here's what you need to know to catch up.
- Figure out How to Recognize Early Indications of Depressions
- Vote in favor of your Favored Kind of Scarf
- Israeli strikes in Gaza kill 25 people, Hamas health authority says
- Figure out How to Assess the Unwavering quality of SUVs for Seniors
- The Solution to Innovative Peculiarity: Analyzing the Fate of Mankind
- Flash flooding causes highways to close to and from Eilat
